Celon Pharma S.A. (WSE: CLN)
Poland
· Delayed Price · Currency is PLN 27.50
-0.10 (-0.36%)
Sep 27, 2024, 3:34 PM CET
Celon Pharma Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 171.54 | 164.39 | 161.92 | 169.56 | 135.48 | 102.25 | Upgrade
|
| Other Revenue | 35.27 | 49.53 | 31.97 | 26.53 | 21.97 | - | Upgrade
|
| Revenue | 206.81 | 213.92 | 193.89 | 196.09 | 157.45 | 102.25 | Upgrade
|
| Revenue Growth (YoY) | -2.00% | 10.33% | -1.12% | 24.54% | 53.99% | -18.36% | Upgrade
|
| Cost of Revenue | 62.64 | 66.82 | 66.46 | 61.72 | 36.64 | 37.99 | Upgrade
|
| Gross Profit | 144.16 | 147.1 | 127.42 | 134.37 | 120.81 | 64.26 | Upgrade
|
| Selling, General & Admin | 119.18 | 111.12 | 107.7 | 90.11 | 83.44 | 62.36 | Upgrade
|
| Other Operating Expenses | 18.7 | 14.32 | 13.52 | 13.5 | 6.93 | -4.32 | Upgrade
|
| Operating Expenses | 188.58 | 175.46 | 165.32 | 144.96 | 124.91 | 58.04 | Upgrade
|
| Operating Income | -44.41 | -28.35 | -37.9 | -10.59 | -4.1 | 6.22 | Upgrade
|
| Interest Expense | -2.51 | -2.66 | -1.67 | -1.55 | -0.67 | -0.19 | Upgrade
|
| Interest & Investment Income | 0.09 | 0.37 | 1.85 | 0.08 | 0.14 | 1.84 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.24 | 0.03 | -0.4 | -2.59 | -0.64 | -0.74 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.72 | 9.53 | 1.11 | -0.57 | -0.75 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -39.36 | -21.08 | -37.01 | -15.22 | -6.02 | 7.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.67 | 1.11 | 0.56 | 0.13 | 0.43 | 0.68 | Upgrade
|
| Pretax Income | -38.69 | -19.97 | -36.45 | -15.09 | -5.59 | 7.81 | Upgrade
|
| Income Tax Expense | 6.79 | 8.16 | 2.83 | -3.48 | -4.67 | -4.13 | Upgrade
|
| Net Income | -45.48 | -28.12 | -39.28 | -11.61 | -0.92 | 11.94 | Upgrade
|
| Net Income to Common | -45.48 | -28.12 | -39.28 | -11.61 | -0.92 | 11.94 | Upgrade
|
| Net Income Growth | - | - | - | - | - | -59.81% | Upgrade
|
| Shares Outstanding (Basic) | 51 | 51 | 51 | 47 | 45 | 45 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 51 | 47 | 45 | 45 | Upgrade
|
| Shares Change (YoY) | 0.04% | 0.04% | 9.32% | 3.74% | - | - | Upgrade
|
| EPS (Basic) | -0.89 | -0.55 | -0.77 | -0.25 | -0.02 | 0.27 | Upgrade
|
| EPS (Diluted) | -0.89 | -0.55 | -0.77 | -0.25 | -0.02 | 0.27 | Upgrade
|
| EPS Growth | - | - | - | - | - | -59.81% | Upgrade
|
| Free Cash Flow | -11.51 | -41.13 | -38.61 | 2.6 | -27.74 | -70 | Upgrade
|
| Free Cash Flow Per Share | -0.23 | -0.81 | -0.76 | 0.06 | -0.62 | -1.56 | Upgrade
|
| Dividend Per Share | 0.080 | 0.080 | 0.090 | 0.290 | 0.070 | 0.080 | Upgrade
|
| Dividend Growth | -11.11% | -11.11% | -68.97% | 314.29% | -12.50% | -66.67% | Upgrade
|
| Gross Margin | 69.71% | 68.76% | 65.72% | 68.53% | 76.73% | 62.85% | Upgrade
|
| Operating Margin | -21.48% | -13.25% | -19.55% | -5.40% | -2.60% | 6.08% | Upgrade
|
| Profit Margin | -21.99% | -13.15% | -20.26% | -5.92% | -0.58% | 11.67% | Upgrade
|
| Free Cash Flow Margin | -5.57% | -19.23% | -19.91% | 1.33% | -17.62% | -68.46% | Upgrade
|
| EBITDA | -13.61 | 8.63 | -2.57 | 27.84 | 25.49 | 26.84 | Upgrade
|
| EBITDA Margin | -6.58% | 4.04% | -1.33% | 14.20% | 16.19% | 26.25% | Upgrade
|
| D&A For EBITDA | 30.8 | 36.99 | 35.33 | 38.43 | 29.59 | 20.62 | Upgrade
|
| EBIT | -44.41 | -28.35 | -37.9 | -10.59 | -4.1 | 6.22 | Upgrade
|
| EBIT Margin | -21.48% | -13.25% | -19.55% | -5.40% | -2.60% | 6.08% | Upgrade
|
| Revenue as Reported | 209.67 | 216.57 | 194.59 | 199.11 | 159.99 | 102.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.